Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Genentech/OSI Tarceva NDA Filing Will Wait For Phase III Monotherapy Data

  • News

Executive Summary

OSI hopes to be in a position to file a Tarceva NDA in early 2004, when data in refractory non-small cell lung cancer patients is expected

You may also be interested in...



Genentech/OSI Tarceva Shows Two-Month Survival Improvement Over Placebo

Genentech/OSI's anti-EGFR agent Tarceva is associated with a two-month improvement in survival for refractory non-small cell lung cancer patients, according to pivotal trial data presented at the American Society of Clinical Oncology annual meeting in New Orleans June 7

Tarceva Survival Benefit Differentiates Oncologic From Iressa – Genentech

The survival benefit seen in Genentech/OSI's Tarceva non-small cell lung cancer monotherapy trial shows it is a "better product" than AstraZeneca's Iressa, Genentech maintained April 26

Tarceva Survival Benefit Differentiates Oncologic From Iressa – Genentech

The survival benefit seen in Genentech/OSI's Tarceva non-small cell lung cancer monotherapy trial shows it is a "better product" than AstraZeneca's Iressa, Genentech maintained April 26

Table

View full table

Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS042571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By